Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by company insiders on July 9, 2015.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports that the listed individuals acquired shares at a price of 1368.97 pence per share through the reinvestment of dividends under the GSK ShareReward Plan.
Important Facts for Investors
- Transaction Type: Directors and PDMRs acquired shares via dividend reinvestment, not open market purchases.
- Transaction Date: July 9, 2015.
- Share Price: 1368.97 pence per share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Share Counts: Acquisitions ranged from 8 shares (Ms E Walmsley) to 57 shares (Mr D S Redfern and Ms C Thomas).